Abstract：Patent ductus arteriosus (PDA) is a common problem encountered in the early neonatal period, particularly in preterm infants. Optimal management of PDA in preterm infants remains controversial. Despite considerable historical and physiological data indicating a persistent PDA may be harmful, robust evidence of long-term benefits or harms from treatment is lacking. This has been equated to a lack of benefit but is also a reflection of the fact that many clinical trials were designed to assess the effects of short-term (2-8 days) rather than prolonged exposure to a PDA. No clinical trials have been designed to assess the effects of prolonged exposure of persistent PDA on morbidity and mortality of very premature infants. Significant changes in management of PDA, i.e., less treatment for PDA, have evolved in recent years. This paper reviews the current literature and evidence for treatment options and research progress of PDA in infants with gestational age of <28 weeks.
TIAN Fang,SHI Wen-Jing. Progress in management of patent ductus arterious in preterm infants with gestational age of <28 weeks[J]. CJCP, 2015, 17(10): 1142-1147.
Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2011, 25(7):42-53.
[2]
Popat H, Kapoor V, Travadi J. Patent ductus arteriosus in infants <29 weeks gestation-outcomes and factors affecting closure[J]. Indian Pediatr, 2012, 49(8):615-620.
[3]
Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants[J]. Cochrane Database Syst Rev, 2010, 24(7):1-174.
[4]
Sosenko IR, Fajardo MF, Claure N, et al. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants:a double-blind randomized controlled trial[J]. J Pediatr, 2012, 160(6):929-935.
[5]
Noori S. Patent ductus arteriosus in the preterm infant:to treat or not to treat?[J]. J Perinatol, 2010, 30(2):31-37.
[6]
Evans N. Preterm patent ductus arteriosus:should we treat it?[J]. J Paediatr Child Health, 2012, 48(9):753-758.
[7]
Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus:are current neonatal treatment options better or worse than no treatment at all?[J]. Semin Perinatol, 2012, 36(2):123-129.
[8]
Ibrahim TK, Haium AA, Chandran S, et al. Current controversies in the management of patent ductus arteriosus in preterm infants[J]. Indian Pediatr, 2014, 51(4):289-294.
[9]
Hammerman C, Bin-Nun A, Kaplan M. Managing the patent ductus arteriosus in the premature neonate:a new look at what we thought we knew[J]. Semin Perinatol, 2012, 36(2):130-138.
[10]
Thankavel PP, Rosenfeld CR, Christie L, et al. Early echocardiographic prediction of ductal closure in neonates ≤ 30 weeks gestation[J]. J Perinatol, 2013, 33(1):45-51.
[11]
Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus?[J]. Eur J Pediatr, 2009, 168(8):907-914.
[12]
Grass B, Baumann P, Arlettaz R, et al. Cardiovascular biomarkers pro-atrial natriuretic peptide and pro-endothelin-1 to monitor ductus arteriosus evolution in very preterm infants[J]. Early Hum Dev, 2014, 90(6):293-298.
[13]
Kulkarni M, Gokulakrishnan G, Price J, et al. Diagnosing significant PDA using natriuretic peptides in preterm neonates:a systematic review[J]. Pediatrics, 2015, 135(2):510-525.
[14]
Occhipinti F, De Carolis MP, De Rosa G, et al. Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus[J]. J Matern Fetal Neonatal Med, 2014, 27(17):1800-1804.
[15]
Czernik C, Metze B, Muller C, et al. Urinary NT-proBNP and ductal closure in preterm infants[J]. J Perinatol, 2013, 33(3):212-217.
[16]
Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure:a randomised controlled trial in extremely low birthweight infants[J]. Arch Dis Child Fetal Neonatal Ed, 2012, 97(4):279-283.
[17]
Gokmen T, Erdeve O, Altug N, et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus[J]. J Pediatr, 2011, 158(4):549-554.
[18]
McNamara PJ. Towards rational management of the patent ductus arteriosus:the need for disease staging[J]. Arch Dis Child Fetal Neonatal Ed, 2007, 92(2):424-427.
[19]
WE B. Patent ductus arteriosus:to treat or not to treat?[J]. Arch Dis Child Fetal Neonatal Ed, 2012, 97(2):80-82.
[20]
Jones LJ, Craven PD, Attia J, et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2011, 96(1):45-52.
[21]
Yadav S, Agarwal S, Maria A, et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in indian preterm neonates:a randomized controlled trial[J]. Pediatr Cardiol, 2014, 35(5):824-830.
[22]
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2013, 27(4):1-153.
[23]
Kluckow M, Jeffery M, Gill A, et al. A randomised placebocontrolled trial of early treatment of the patent ductus arteriosus[J]. Arch Dis Child Fetal Neonatal Ed, 2014, 99(2):F99-F104.
[24]
Carmo KB, Evans N, Paradisis M. Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography[J]. J Pediatr, 2009, 155(6):819-822.
[25]
Rosito G, Sum K, Chorne N. Comparison of two neonatal indomethacin protocols:efficacy and outcome for patent ductus arteriosus closure[J]. J Clin Pharm Ther, 2010, 35(5):589-592.
[26]
Irmesi R, Marcialis MA, Van Den Anker J, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) in the management of patent ductus arteriosus (PDA) in preterm infants and variations in attitude in clinical practice:a flight around the world[J]. Curr Med Chem, 2014, 21(27):3132-3152.
[27]
Yoshimoto SS. Prohylactic indomethacin in extremely premature infants between 23 and 24 weeks gestation[J]. Pediatr Int, 2010, 52(2):374-377.
[28]
Yanowitz TD, Reese J, Gillam-Krakauer M, et al. Superior mesenteric artery blood flow velocities following medical treatment of a patent ductus arteriosus[J]. J Pediatr, 2014, 164(3):661-663.
[29]
Clyman R, Wickremasinghe A, Jhaveri N, et al. Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus[J]. J Pediatr, 2013, 163(2):406-411.
[30]
Chan NM, Law CW, Kwan KF. Ibuprofen versus indomethacin treatment of patent ductus arteriosus:comparative effectiveness and complications[J]. Hong Kong Med J, 2014, 20(3):205-212.
[31]
Kluckow M. Oral Ibuprofen and the patent ductus arteriosus:a new approach to an old problem[J]. J Pediatr (Rio J), 2013, 89(1):4-5.
[32]
Neumann R, Schulzke SM, Buhrer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants:a systematic review and meta-analysis[J]. Neonatology, 2012, 102(1):9-15.
Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants:a randomized controlled study[J]. Clin Pharmacol Ther, 2012, 91(4):590-596.
[35]
Sajan SS, Mahajan V. High-dose Ibuprofen therapy for patent ductus arteriosus in extremely preterm neonates:do we have a final answer?[J]. Clin Pharmacol Ther, 2012, 92(5):557-558.
[36]
Attridge JT. New insights into spontaneous intestinal perforation using a national data set:SIP is associated with early indomethacin exposure[J]. J Perinatol, 2006, 26(2):93-99.
Kessel I, Waisman D, Lavie-Nevo K, et al. Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure:a case series[J]. J Matern Fetal Neonatal Med, 2014, 27(16):1719-1721.
[39]
Ozdemir OM, Dogan M, Kucuktasci K, et al. Paracetamol therapy for patent ductus arteriosus in premature infants:a chance before surgical ligation[J]. Pediatr Cardiol, 2014, 35(2):276-279.
[40]
Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants:a randomized controlled trial[J]. J Pediatr, 2014, 164(3):510-514.
[41]
Fonseca E, Georgiev SG, Gorenflo M, et al. Patent ductus arteriosus in preterm infants:benefits of early surgical closure[J]. Asian Cardiovasc Thorac Ann, 2014, 22(4):391-396.
[42]
Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment[J]. J Pediatr, 2010, 157(3):381-387.
[43]
Weisz DE, More K, McNamara PJ, et al. PDA ligation and health outcomes:a meta-analysis[J]. Pediatrics, 2014, 133(4):e1024-e1046.
[44]
Kozlov I, Novozhilov VA, Ezhova IV, et al. Thoracotomy and thoracoscopy in the treatment of patent arterial duct in infants weighing less than 2 500 g[J]. Khirurgiia (Mosk), 2014, 95(1):64-72.
[45]
Zahn EM, Nevin P, Simmons C, et al. A novel technique for transcatheter patent ductus arteriosus closure in extremely preterm infants using commercially available technology[J]. Catheter Cardiovasc Interv, 2014, 85(2):240-248.
